

Mouse Phenotype

	-log10(Binomial p value)
decreased megakaryocyte cell number	15.09
abnormal foot pad morphology	14.69
abnormal blood cell physiology	14.34
absent barrels in primary somatosensory cortex	14.34
abnormal hematopoietic system physiology	13.16
abnormal megakaryocyte morphology	12.74
decreased thermal nociceptive threshold	12.61
abnormal splenocyte number	12.24
abnormal megakaryocyte progenitor cell morphology	12.15
small vertebrae	12.08
abnormal splenocyte morphology	12.04
abnormal skeleton development	12.01
abnormal bone marrow hematopoietic cell morphology	12.01
hyperpigmentation	11.98
abnormal professional antigen presenting cell morphology	11.62
decreased osteoblast cell number	11.59
abnormal fat cell morphology	11.56
abnormal trabecular bone volume	11.25
abnormal epiphyseal plate morphology	11.23
increased foot pad pigmentation	11.21
abnormal motor capabilities/coordination/movement	11.18
abnormal filiform papillae morphology	11.14
decreased organ/body region tumor incidence	11.13
abnormal gas homeostasis	11.01
increased insulin sensitivity	10.86
decreased osteoclast cell number	10.75
loss of vibrissae	10.70
abnormal cochlear hair cell development	10.68
abnormal hematopoietic cell number	10.64
increased bone trabecula number	10.61
abnormal hematopoietic cell morphology	10.59
abnormal myeloid cell morphology	10.47
decreased hematopoietic cell number	10.46
abnormal hormone level	10.43
decreased tumor incidence	10.37
increased osteoma incidence	10.28
abnormal bone trabecula morphology	10.24
increased trabecular bone volume	10.14
abnormal bone volume	10.07
abnormal long bone epiphyseal plate morphology	10.03
abnormal definitive hematopoiesis	9.95
integument phenotype	9.91
abnormal osteoclast cell number	9.85
abnormal osteoclast morphology	9.85
abnormal hemopoiesis	9.66
increased organ/body region tumor incidence	9.57
increased bone volume	9.48
abnormal blood cell morphology	9.42
absent lactotrophs	9.41
decreased macrophage cell number	9.39
arrested B cell differentiation	9.35
abnormal organ/body region tumor incidence	9.34
increased intestinal adenocarcinoma incidence	9.30
decreased somatotroph cell number	9.24
osteopetrosis	9.23
abnormal lactotroph morphology	9.20
abnormal osteoblast cell number	9.12
abnormal blood cell morphology/development	9.03
abnormal osteoblast morphology	8.99
abnormal liver morphology	8.97
abnormal fat pad morphology	8.94
abnormal hematopoietic system morphology/development	8.92
abnormal heart layer morphology	8.84
abnormal bone remodeling	8.80
abnormal skin morphology	8.77
abnormal thyrotroph morphology	8.76
increased granulosa cell tumor incidence	8.70
abnormal cell differentiation	8.70
hematopoietic system phenotype	8.66
abnormal leukocyte morphology	8.66
decreased mammary gland tumor incidence	8.63
abnormal adaptive immunity	8.62
abnormal mononuclear cell morphology	8.59
abnormal immune system cell morphology	8.58
liver/biliary system phenotype	8.55
increased gland tumor incidence	8.53
abnormal posterior eye segment morphology	8.51
decreased integument system tumor incidence	8.49
abnormal appendicular skeleton morphology	8.48
abnormal macrophage morphology	8.37
abnormal professional antigen presenting cell physiology	8.32
increased bone mass	8.28
perinatal lethality, complete penetrance	8.27
increased integument system tumor incidence	8.26
decreased gland tumor incidence	8.24
abnormal hepatobiliary system morphology	8.19
increased tumor incidence	8.16
perinatal lethality, incomplete penetrance	8.10
abnormal epidermal layer morphology	8.06
abnormal bone resorption	8.04
abnormal urinary bladder urothelium morphology	8.03
abnormal macrophage cell number	8.00
increased urinary system tumor incidence	7.90
increased urinary bladder carcinoma incidence	7.87
increased pituitary gland tumor incidence	7.87
abnormal abdominal fat pad morphology	7.85
abnormal testis size	7.85
decreased splenocyte number	7.83
abnormal spleen morphology	7.82
decreased gonadotroph cell number	7.81
abnormal ear morphology	7.78
abnormal thymus lobule morphology	7.77
small testis	7.72
abnormal leukocyte physiology	7.72
abnormal circulating hormone level	7.67
small gonad	7.66
abnormal operant conditioning behavior	7.63
abnormal immune cell physiology	7.63
abnormal cell-mediated immunity	7.58
abnormal foot pigmentation	7.48
abnormal somatotroph morphology	7.46
abnormal skeleton morphology	7.44
decreased bone trabecula number	7.43
abnormal osteoclast physiology	7.39
increased nervous system tumor incidence	7.38
decreased bone mineralization	7.37
abnormal bone structure	7.36
decreased bone resorption	7.30
abnormal liver physiology	7.27
abnormal suckling behavior	7.27
abnormal skin condition	7.23
abnormal primary sex determination	7.21
abnormal Harderian gland size	7.19
abnormal metabolism	7.16
decreased brain size	7.14
abnormal cartilage morphology	7.14
abnormal tumor incidence	7.09
skeleton phenotype	7.00
increased leukocyte cell number	7.00
abnormal mononuclear phagocyte morphology	6.99
abnormal locomotor activation	6.96
abnormal seizure response to pharmacological agent	6.93
altered tumor susceptibility	6.91
prenatal lethality, incomplete penetrance	6.91
gastrointestinal hemorrhage	6.89
increased mammary gland tumor incidence	6.89
abnormal urothelium morphology	6.87
abnormal forebrain morphology	6.86
abnormal erythroid lineage cell morphology	6.85
absent midbrain	6.84
abnormal sex determination	6.81
abnormal testis morphology	6.80
abnormal lymph organ size	6.66
abnormal vibrissa morphology	6.63
abnormal leukocyte cell number	6.58
thin epidermis	6.55
abnormal hepatobiliary system physiology	6.55
increased gastrointestinal tumor incidence	6.54
abnormal osteoclast differentiation	6.48
hearing/vestibular/ear phenotype	6.47
abnormal long bone morphology	6.47
increased hematopoietic cell number	6.44
abnormal osteoblast differentiation	6.40
rostral body truncation	6.40
increased birth weight	6.38
abnormal immune system physiology	6.36
neoplasm	6.31
abnormal heart size	6.31
abnormal voluntary movement	6.29
abnormal internal male genitalia morphology	6.28
decreased leukocyte cell number	6.25
abnormal outer ear morphology	6.22
decreased bone volume	6.21
abnormal seminiferous tubule morphology	6.19
gastrointestinal tract polyps	6.18
abnormal brown fat cell morphology	6.16
abnormal macrophage physiology	6.14
increased intestinal adenoma incidence	6.11
abnormal male reproductive gland morphology	6.05
abnormal coat appearance	6.05
abnormal immune system organ morphology	5.98
short vibrissae	5.96
increased susceptibility to pharmacologically induced seizures	5.95
increased susceptibility to induction of seizure by inducing agent	5.95
abnormal adipose tissue morphology	5.94
abnormal bone marrow cavity morphology	5.92
abnormal male genitalia morphology	5.92
abnormal lymphopoiesis	5.88
increased birth body size	5.82
adipose tissue phenotype	5.82
abnormal circulating pituitary hormone level	5.79
abnormal locomotor behavior	5.78
increased circulating pituitary hormone level	5.78
abnormal body length	5.75
abnormal retina morphology	5.71
increased ovary tumor incidence	5.71
abnormal trabecular bone morphology	5.70
abnormal cerebral hemisphere morphology	5.70
abnormal sex gland morphology	5.69
abnormal coat/ hair morphology	5.69
abnormal muscle morphology	5.65
abnormal ocular fundus morphology	5.65
abnormal chondrocyte morphology	5.64
increased prostate gland tumor incidence	5.62
abnormal endocrine gland morphology	5.58
vision/eye phenotype	5.52
abnormal circulating gonadotropin level	5.48
abnormal nursing	5.47
abnormal phagocyte morphology	5.43
increased carcinoma incidence	5.41
increased body weight	5.38
perinatal lethality	5.35
limbs/digits/tail phenotype	5.29
decreased bone ossification	5.29
decreased B cell number	5.25
increased pituitary hormone level	5.22
abnormal telencephalon morphology	5.11
abnormal axial skeleton morphology	5.07
domed cranium	5.05
increased classified tumor incidence	5.04
increased adenoma incidence	5.03
abnormal adenoma incidence	5.03
abnormal mammary gland morphology	5.01
abnormal leukopoiesis	5.00
abnormal compact bone morphology	4.99
abnormal bone ossification	4.98
abnormal seizure response to inducing agent	4.96
increased body size	4.96
abnormal classified tumor incidence	4.95
decreased length of long bones	4.95
abnormal spleen size	4.92
increased malignant tumor incidence	4.91
abnormal behavioral response to xenobiotic	4.91
abnormal pituitary hormone level	4.89
abnormal embryonic epiblast morphology	4.85
ear inflammation	4.83
abnormal ovary morphology	4.83
abnormal limb morphology	4.82
enlarged spleen	4.82
abnormal bone mineralization	4.81
increased lymphocyte cell number	4.79
abnormal eating behavior	4.73
abnormal T cell differentiation	4.73
abnormal skin pigmentation	4.71
abnormal thymus medulla morphology	4.69
increased small intestine adenocarcinoma incidence	4.67
abnormal innate immunity	4.66
abnormal hindlimb morphology	4.61
abnormal long term potentiation	4.60
abnormal neuron number	4.58
abnormal maternal nurturing	4.56
anemia	4.55
abnormal reproductive system morphology	4.51
abnormal inflammatory response	4.51
abnormal female reproductive gland morphology	4.50
prenatal lethality, complete penetrance	4.48
abnormal bilaminar embryonic disc	4.48
kinked tail	4.44
increased double-negative T cell number	4.44
increased reproductive system tumor incidence	4.44
abnormal skeleton physiology	4.41
abnormal ear physiology	4.38
abnormal intestine morphology	4.38
abnormal skin coloration	4.35
abnormal internal female genitalia morphology	4.31
small seminiferous tubules	4.30
abnormal myeloid leukocyte morphology	4.28
abnormal fluid regulation	4.28
abnormal skin appearance	4.26
abnormal ovarian follicle morphology	4.26
abnormal skin adnexa morphology	4.22
abnormal respiratory system physiology	4.20
abnormal consumption behavior	4.19
abnormal limb bone morphology	4.19
abnormal sensory capabilities/reflexes/nociception	4.16
abnormal craniofacial morphology	4.10
abnormal osteoblast physiology	4.10
craniofacial phenotype	4.09
embryonic lethality between implantation and somite formation	4.08
abnormal female genitalia morphology	4.07
increased ear pigmentation	4.07
hepatic necrosis	4.07
abnormal female reproductive system morphology	4.06
decreased birth body size	4.05
abnormal seminiferous tubule size	4.03
abnormal thyroid follicle morphology	4.03
abnormal birth body size	4.02
abnormal cranium morphology	3.99
thick skin	3.90
abnormal craniofacial bone morphology	3.87
arrested T cell differentiation	3.85
abnormal gland physiology	3.80
lethality throughout fetal growth and development	3.75
hemorrhage	3.75
aneuploidy	3.74
abnormal bony labyrinth	3.66
liver hyperplasia	3.60
abnormal breathing pattern	3.56
abnormal circulating parathyroid hormone level	3.56
abnormal erythrocyte cell number	3.45
abnormal heart rate	3.45
increased circulating prolactin level	3.39
abnormal mammary gland development	3.37
increased thyrotroph cell number	3.36
increased prolactin level	3.35
abnormal thymus cortex morphology	3.31
abnormal liver regeneration	3.24
abnormal mandible morphology	3.18
postnatal growth retardation	3.14
slow postnatal weight gain	3.14
embryonic lethality during organogenesis	3.03
decreased mean systemic arterial blood pressure	3.02
decreased thymocyte number	3.02
abnormal alcohol consumption	3.01
abnormal respiratory function	3.01
small ovary	3.01
abnormal reflex	2.99
abnormal social/conspecific interaction	2.95
abnormal synaptic dopamine release	2.95
postnatal lethality, incomplete penetrance	2.92
decreased testis weight	2.89
abnormal tail morphology	2.87
absent long term depression	2.85
abnormal heartbea	2.84
abnormal fear/anxiety-related behavior	2.79
abnormal exocrine gland morphology	2.76
abnormal ovary size	2.74
abnormal thymus morphology	2.71
abnormal duodenum morphology	2.66
abnormal long bone epiphysis morphology	2.64
decreased alcohol consumption	2.63
abnormal testis weight	2.60
decreased sensitivity to induced morbidity/mortality	2.58
decreased circulating parathyroid hormone level	2.36
decreased tumor growth/size	2.28
abnormal long term depression	2.18
abnormal endocrine gland physiology	2.16